R&D
R&D
Professional Profile
Current Positions
-
R&D Center Director, YEPBIO
Previous Experience
-
R&D Center Director, Medi-Helpline
-
Korea Ginseng Corporation
-
Whan In Pharmaceutical
-
SK Chemicals
-
Korea Ministry of Food and Drug Safety (K-MFDS)
Education & Certification
-
Doctor of Pharmacy, Kyung Hee University
-
Certified Technology Transfer Agent
COO In-Ho, Jung
Development of First in class Drugs
Research Featured in Top-tier Scientific Journals
• Cell. 2011 Mar 4;144(5):689-702
• PNAS. 2015 Sep 15;112(37):11696-701
• Cell Rep. 2017 Jan 24;18(4):918-932
• Sci Transl med. 2021 Jul 28;13(604):eaax8891.
• Brain. 2021 Dec 31;144(12):3674-3691.
• Parkin dysfunction causes PARIS accumulation in the substantia nigra
• PARIS is a transcriptional repressor that inhibits PGC-1⍺, a mitochondrial regulator
• PARIS accumulation causes dopaminergic neuron death
1. The first pioneering discovery linking PARIS to Parkinson’s disease.
PARIS(ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
This discovery is currently being translated into preclinical and clinical studies.
2.Our pipeline is backed by multiple independent follow-up studies
• PARIS - PINK1 Relation
• PARIS - c-Abl Relation
• PARIS - NLRP3 Relation
• PARIS - a-synuclein Relation
Accumulation of PARIS
Targeting PARIS is our core strategy for treating PD
Development of Early Diagnosis Kit
Advantages of Autoantibody-Based Strategies
•Early Detection
Autoantibodies are generated from the very onset of pathological changes, enabling ultra-early diagnosis of Parkinson’s disease.
•Disease Staging
Serve as biomarkers that reflect the progression stage of the disease, allowing for stage-specific treatment strategies.
•Simple & Rapid Testing
Requires only a small blood sample to deliver quick, quantitative results — with no need for signal amplification procedures.
Advantages of Peptide Epitope Mapping for Diagnostics
•Enhanced Specificity & Sensitivity
By leveraging multiple peptide epitopes associated with Parkinson’s disease, our strategy maximizes diagnostic precision and
minimizes false results.
•Rapid & Reliable Biomarker Development
Targeted mapping of immunodominant regions enables efficient identification of clinically relevant biomarkers with strong diagnostic
performance.
•Multiplex-Ready & Scalable Platform
Optimized for integration into multiplex diagnostic platforms, allowing simultaneous detection of multiple epitopes for comprehensive
early-stage and progression-based analysis.
Stage 3 : Peptide-Based Multiplex Diagnostic Development
YPD-HAT (High-sensitive Autoantibody Test)
YPD-ASK (Anytime Self-test Kit)
• Hospital
• Health Checkup Centers
• Clinics / Nursing Homes
• Public Health Centers
• Individuals
• Pharmacies / Med. Equipment Suppliers
(Including Online)
• Remote Areas & Islands
• Medically Underserved Communities
•NHIC ‘Basic Exam’ Listing &
Medical Fee Application
•Regional PD Screening Centers Designation
•Min. HQ Margin / Standard Pricing
•Higher Margin for Pharmacies & Suppliers
•Free Trials: LTC Hospitals & Daycare Centers
•KFDA-Approved ‘New Medical Devic’
< ELISA Kit >
< Rapid kit>
Strategy for Peptide-Based Multiplex Diagnostic Development
•Integrated Biomarker Optimization
Disease-specific autoantibody biomarkers, discovered through high-throughput screening, are refined via peptide epitope mapping to ensure
maximum specificity and clinical relevance.
•Dual-Platform Diagnostic Development
We are developing two diagnostic formats:
•YPD-HAT: An ELISA-based high-throughput test kit optimized for laboratory-scale mass screening.
•YPD-ASK: A rapid, user-friendly point-of-care kit for real-time self-diagnosis anytime, anywhere.
•Multiplex Precision & Scalability
By integrating multiple validated peptide biomarkers, both platforms offer enhanced sensitivity, broad diagnostic coverage, and scalability for
clinical and personal healthcare settings.
